# FG-3246 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/fg-3246

> The next catalyst for FG-3246, sponsored by KYNTRA BIO, INC. (KYNB), is its topline data readout, Mar to Jun 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | FG-3246 |
| Codes | FG-3246, FOR46 |
| Sponsor | KYNTRA BIO, INC. (KYNB) https://sec-api.dev/companies/kynb/catalysts |
| Indications | [mcrpc](https://sec-api.dev/indications/mcrpc), with mcrpc, mcrpc, along with the exploratory analysis of fg-3180, metastatic castration-resistant prostate cancer, with interim results, mcrpc, currently, mcrpc in mid-2025, [Metastatic Castration-Resistant Prostate Cancer](https://sec-api.dev/indications/metastatic-castration-resistant-prostate-cancer) |
| Modality |  |
| FDA designations | orphan |

## Timeline

### May 2024: interim data readout

- Status: completed, positive. Date confidence: month. Stage: 1/2. Indication: mCRPC.
- First seen 2024-11-12, last confirmed 2025-11-10.
- SEC Form 10-Q (accession 0001193125-25-274241): "In May 2024, the University of California, San Francisco ("UCSF") presented positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with mCRPC at the 2024 American Society of Clinical Oncology Annual Meeting." https://www.sec.gov/Archives/edgar/data/921299/000119312525274241/fgen-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-106549): "In May 2024, the University of California, San Francisco ("UCSF") presented positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with mCRPC at the 2024 American Society of Clinical Oncology Annual Meeting." https://www.sec.gov/Archives/edgar/data/921299/000095017025106549/fgen-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-069203): "In May 2024, the University of California, San Francisco ("UCSF") presented positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with mCRPC at the 2024 American Society of Clinical Oncology Annual Meeting." https://www.sec.gov/Archives/edgar/data/921299/000095017025069203/fgen-20250331.htm
- SEC Form 10-Q (accession 0000950170-24-125388): "In May 2024, the University of California, San Francisco ("UCSF") presented positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with mCRPC at the 2024 American Society of Clinical Oncology Annual Meeting." https://www.sec.gov/Archives/edgar/data/921299/000095017024125388/fgen-20240930.htm

### Q1 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: mCRPC.
- First seen 2024-11-12, last confirmed 2025-03-31.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-125332): "Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC anticipated in 1Q 2025" https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-125332): "Anticipate initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC in 1Q 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/fgen-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-24-125388): "We have met with the FDA to discuss the development pathway of FG-3246, and we anticipate initiation of a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017024125388/fgen-20240930.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-046978): "Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC expected by mid-2025" https://www.sec.gov/Archives/edgar/data/921299/000095017025046978/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-046978): "The Company anticipates initiating the Phase 2 monotherapy dose optimization study of FG-3246 in patients with mCRPC by mid-2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025046978/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-040248): "Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected by mid-2025" https://www.sec.gov/Archives/edgar/data/921299/000095017025040248/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-040248): ""We entered 2025 optimistic about our future, highlighted by the planned initiation of the Phase 2 monotherapy trial of FG-3246, our first-in-class ADC targeting CD46 for the treatment of mCRPC, by mid-2025," said Thane Wettig, Chief Executive Officer." https://www.sec.gov/Archives/edgar/data/921299/000095017025040248/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-040248): "Anticipate initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC by mid-2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025040248/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-040248): "The initiation of the Phase 2 monotherapy dose optimization trial for FG-3246 in metastatic castration-resistant prostate cancer is anticipated by mid-2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025040248/fgen-ex99_1.htm
- SEC prospectus (424B) (accession 0001193125-25-033535): "We anticipate initiation of a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/921299/000119312525033535/d936393d424b5.htm
- SEC Form 10-K (accession 0000950170-25-040280): "We anticipate initiation of a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC in mid-2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025040280/fgen-20241231.htm
- SEC Form 10-K (accession 0000950170-25-040280): "We have met with the FDA to discuss the development pathway of FG-3246, and we anticipate initiation of a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC in the mid-2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025040280/fgen-20241231.htm

### 1H 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2. Indication: mCRPC.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-125332): "Topline results from the Phase 2 portion of the investigator-sponsored Phase 1b/2 study conducted by UCSF of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 1H 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/fgen-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-24-125388): "We expect topline results from the Phase 2 portion of this study of FG-3246 in combination with enzalutamide in the first half of 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017024125388/fgen-20240930.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-125332): ""Having implemented our cost reduction plan, we are well positioned to advance FG-3246, with topline results from the Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide at the University of California San Francisco (UCSF) on track for the first half of 2025, and the anticipated start of our Phase 2 monotherapy trial in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/fgen-ex99_1.htm

### Q4 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: mCRPC, along with the exploratory analysis of FG-3180.
- First seen 2025-05-12, last confirmed 2025-09-02.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-112341): ""With a rejuvenated capital structure, we are on track to commence the Phase 2 monotherapy trial of FG-3246 in mCRPC imminently as well as submit the Phase 3 protocol for roxadustat in anemia associated with lower-risk MDS in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025112341/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-106534): "Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025" https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-106534): "Trial initiation activities for the Phase 2 monotherapy trial of FG-3246 are progressing, and we expect to start the trial in the third quarter of 2025," said Thane Wettig, Chief Executive Officer, FibroGen." https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-106534): "Trial initiation activities for the Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC remain ongoing, with an expected trial start in the third quarter of 2025 upon the close of the sale of FibroGen China." https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-106534): "The initiation of the Phase 2 monotherapy dose optimization trial for FG-3246 in metastatic castration-resistant prostate cancer is anticipated in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-069159): ""We continue to focus on our most important strategic priority of advancing our lead asset, FG-3246, with the initiation of the Phase 2 monotherapy dose optimization study in mCRPC, expected to start in the third quarter of 2025," said Thane Wettig, Chief Executive Officer, FibroGen." https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-069159): "Anticipate initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-069159): "The initiation of the Phase 2 monotherapy dose optimization trial for FG-3246 in metastatic castration-resistant prostate cancer is anticipated in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/fgen-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-25-106549): "We anticipate initiation of a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC, along with the exploratory analysis of FG-3180, in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025106549/fgen-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-106549): "If the sale of FibroGen International is delayed past the third quarter of 2025, we may need to delay initiation of our planned Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC, currently expected in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025106549/fgen-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-069203): "The Company anticipates initiation of a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC, along with the exploratory analysis of FG-3180, in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025069203/fgen-20250331.htm
- SEC Form 10-Q (accession 0000950170-25-069203): "We anticipate initiation of a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC, along with the exploratory analysis of FG-3180, in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025069203/fgen-20250331.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: mCRPC.
- First seen 2025-03-17, last confirmed 2025-08-11.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-069159): "Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 4Q 2025" https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-069159): "Topline results from the Phase 2 portion of the investigator-sponsored Phase 1b/2 study conducted by UCSF of FG-3246 in combination with enzalutamide in patients with mCRPC expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-046978): "FG-3246 is also being evaluated in combination with enzalutamide in an investigator-sponsored study with topline results from the Phase 2 portion of the study anticipated in 2H 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025046978/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-046978): "FG-3246 is currently in an ongoing Phase 1/2 study being conducted at UCSF to evaluate it in combination with enzalutamide with topline data from the Phase 2 portion of the study expected in the second half of 2025, and a biomarker trial using a PET biomarker for CD46 using the same antibody backbone." https://www.sec.gov/Archives/edgar/data/921299/000095017025046978/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-040248): "Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 2H 2025" https://www.sec.gov/Archives/edgar/data/921299/000095017025040248/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-040248): "Topline results from the Phase 2 portion of the investigator-sponsored Phase 1b/2 study conducted by UCSF of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 2H 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025040248/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-046978): ""We are looking forward to advancing FG-3246 in the clinic and remain on track for initiating the Phase 2 monotherapy study by mid-2025 as well as disclosing topline results from the combination trial of FG-3246 and enzalutamide in the second half of 2025," added Thane Wettig, Chief Executive Officer of FibroGen." https://www.sec.gov/Archives/edgar/data/921299/000095017025046978/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-106534): "Topline results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 4Q 2025" https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-106534): "Topline results from the investigator-sponsored Phase 1b/2 study, conducted by UCSF, of FG-3246 in combination with enzalutamide in patients with mCRPC expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/fgen-ex99_1.htm

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1/2. Indication: mCRPC.
- First seen 2025-11-10, last confirmed 2026-01-07.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-274192): "Topline results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected to be presented at a medical conference in 1Q 2026" https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-006327): "Topline results from the investigator-sponsored Phase 1b/2 study, conducted by UCSF, of FG-3246 in combination with enzalutamide in patients with mCRPC are expected to be presented at ASCO GU in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/fgen-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-274192): "Topline results from the investigator-sponsored Phase 1b/2 study, conducted by UCSF, of FG-3246 in combination with enzalutamide in patients with mCRPC are expected to be presented at a medical conference in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/fgen-ex99_1.htm

### Q4 2026: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: with mCRPC.
- First seen 2025-11-10, last confirmed 2026-08-31.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-349141): "Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026" https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/kynb-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-349141): "Enrollment in the Phase 2 monotherapy trial of FG-3246, a potential first-in-class ADC targeting CD46 in mCRPC continues; interim analysis is on track for the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/kynb-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-216731): "Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026" https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/kynb-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-216731): "We are encouraged by the pace of enrollment in our Phase 2 trial of FG-3246 in patients with mCRPC and are on track for the interim analysis in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/kynb-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-216731): "Phase 2 monotherapy trial of FG-3246, a potential first-in-class ADC targeting CD46, in mCRPC is actively enrolling and remains on track for interim analysis in the fourth quarter of 2026" https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/kynb-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-108324): "Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for interim analysis in 2H 2026" https://www.sec.gov/Archives/edgar/data/921299/000119312526108324/kynb-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-108324): ""Our Phase 2 monotherapy trial of FG-3246 is progressing as planned, with interim results expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/921299/000119312526108324/kynb-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-108324): "Phase 2 monotherapy trial of FG-3246, a potential first-in-class ADC targeting CD46, in mCRPC is actively enrolling and remains on track for interim analysis in the second half of 2026" https://www.sec.gov/Archives/edgar/data/921299/000119312526108324/kynb-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-349183): "We are actively enrolling our Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of patients with mCRPC in the post-ARPI and pre-chemotherapy setting, with interim results expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/921299/000119312526349183/kynb-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-219374): "We are actively enrolling our Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of patients with mCRPC in the post-ARPI and pre-chemotherapy setting, with interim results expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/921299/000119312526219374/kynb-20260331.htm
- SEC Form 10-K (accession 0001193125-26-108346): "We are actively enrolling our Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of patients with mCRPC in the post-ARPI and pre-chemotherapy setting, with interim results expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/921299/000119312526108346/kynb-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-274241): "We initiated a Phase 2 monotherapy, dose-optimization study of FG-3246 for the treatment of mCRPC in the third quarter of 2025, with interim results expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/921299/000119312525274241/fgen-20250930.htm

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Metastatic Castration-Resistant Prostate Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06842498 (A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Kyntra Bio." https://clinicaltrials.gov/study/NCT06842498

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Metastatic Castration-Resistant Prostate Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06842498 (A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Kyntra Bio." https://clinicaltrials.gov/study/NCT06842498

## Same indication

- [Mevrometostat](https://sec-api.dev/pdufa/mevrometostat) (PFE)
- [Vudalimab + carboplatin + cabazitaxel](https://sec-api.dev/pdufa/vudalimab-carboplatin-cabazitaxel) (XNCR)

Calendar months: [March 2028](https://sec-api.dev/fda-calendar/2028-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/fg-3246.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "FG-3246 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/fg-3246

```bibtex
@misc{secapidev_pdufa_fg_3246_20261116,
  title        = {FG-3246 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/fg-3246}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_fg_3246_20261116","title":"FG-3246 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/fg-3246","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
